Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700048 · ClinicalTrials.gov registry record · Phase 1
Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
A Phase 1 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02700048 is a Phase 1 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 11 participants.
The verdict
NCT02700048, a Phase 1 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a single center, single-blind randomized cross over design trial that will compare the impact of intra-nasal naloxone vs. intra-nasal saline administration during experimental hypoglycemia on day one on responses to experimental hypoglycemia on day two. Investigators intend to enroll 18 individuals to obtain the complete data sets from 15 participants. Expected duration of subject participation is 10-12 weeks. This study will consist of two 2-day intervention visits separated by approximately 8 weeks.
Interventions
- DRUG intra-nasal naloxone
- DRUG Intra-nasal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-06 |
| Est. Completion | 2021-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02700048
The ClinicalTrials.gov registry entry for NCT02700048 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which intra-nasal naloxone is the first listed.
NCT02700048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02700048 about?
NCT02700048 is a clinical study titled "Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia". This is a single center, single-blind randomized cross over design trial that will compare the impact of intra-nasal naloxone vs. intra-nasal saline administration during experimental hypoglycemia on day one on responses to experimental hypoglycemia on day two. Investigators intend to enroll 18 indi...
What is the current status of trial NCT02700048?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-06. Estimated completion is 2021-07.
What interventions are being tested in trial NCT02700048?
The interventions under investigation include: intra-nasal naloxone (DRUG), Intra-nasal saline (DRUG).
Who is sponsoring clinical trial NCT02700048?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.